Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment
Autore:
Jazwinska-Tarnawska, E; Orzechowska-Juzwenko, K; Niewinski, P; Rzemislawska, Z; Loboz-Grudzien, K; Dmochowska-Perz, M; Slawin, J;
Indirizzi:
Wroclaw Med Univ, Chair & Dept Clin Pharmacol, PL-50345 Wroclaw, Poland Wroclaw Med Univ Wroclaw Poland PL-50345 macol, PL-50345 Wroclaw, Poland Marciniak T Hosp, Dept Cardiol, Wroclaw, Poland Marciniak T Hosp WroclawPoland k T Hosp, Dept Cardiol, Wroclaw, Poland
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
fascicolo: 7, volume: 39, anno: 2001,
pagine: 288 - 292
SICI:
0946-1965(200107)39:7<288:TIOCPO>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
OXIDATION; SPARTEINE; METABOLISM;
Keywords:
oxidation phenotype; propafenone (PPF); atrial fibrillation (AF);
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
9
Recensione:
Indirizzi per estratti:
Indirizzo: Jazwinska-Tarnawska, E Wroclaw Med Univ, Chair & Dept Clin Pharmacol, Bujwida St 44, PL-50345 Wroclaw, Poland Wroclaw Med Univ Bujwida St 44 WroclawPoland PL-50345
Citazione:
E. Jazwinska-Tarnawska et al., "The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment", INT J CL PH, 39(7), 2001, pp. 288-292

Abstract

Objective: Propafenone (PPF) is an antiarrhythmic, Class Ic agent. Its metabolism is genetically controlled by a cytochrome P450 isoenzyme named CYP2D6, which shows polymorphism in human population. The aim of this paper wasto determine the correlation between the antiarrhythmic efficacy of PPF and the oxidation phenotype. Subjects and material: The study group consistedof 42 patients, aged 36 to 75 years, suffering from paroxysmal atrial fibrillation (AF). The oxidation phenotype was described by the metabolic ratio(MR) of sparteine. The MR value separated the group of poor metabolizers (MR > 20) from the group of extensive metabolizers (MR < 20) with the subgroup of very extensive metabolizers (MR < 1). Method: The study was conductedduring a 3-month PPF therapy for the prophylaxis of paroxysmal atrial fibrillation. PPF was given orally, 300 - 450 mg/day. The oxidation phenotype was checked prior to the administration of PPF. Serum concentration of PPF at 7, 11 days and the end of PPF therapy were determined. Statistical analysis of data was performed with the chi (2) test and the Pearson's correlation methods. Results: In the group of 42 patients, PPF therapy was 100% effective in poor metabolizers (PM). In extensive metabolizers (EM), 61% efficacy was observed with efficacy 0% in very extensive metabolizers (VEM). The correlation between oxidation phenotype and the ability to maintain sinus rhythm (SR) was statistically significant (r = 0.414, p < 0.05). Conclusions:The antiarrhythmic efficacy of propafenone depends on the oxidation phenotype; 100% efficacy occurred in the group of poor metabolizers whereas PPF, at the dose tested, was ineffective in very extensive metabolizers.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 11:21:46